At what enterprise value was STADA acquired in 2017?

During the acquisition of STADA by BAIN CAPITAL / CINVEN in 2017, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 3b - 100b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of STADA when it was acquired by BAIN CAPITAL / CINVEN?

The estimated EV/EBITDA multiple for STADA is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.4x. Join our community for free to access full valuation data and industry trends.

When was STADA acquired by BAIN CAPITAL / CINVEN?

STADA was acquired by BAIN CAPITAL / CINVEN in 2017.

What was the revenue of STADA at the time of the deal?

The revenue of STADA at the time of the deal is estimated to be in the range of 1b - 3b EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of STADA during the acquisition?

STADA's EBITDA is estimated to be in the range of 250M - 500M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the STADA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the STADA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.stada.com/blog/posts/2017/april/to-the-shareholders-of-stada-arzneimittel-ag-stada-supports-voluntary-public-tender-offer-by-bain-capital-and-cinven#:~:text=The%20offer%20estimates%20STADA's%20equity,we%20have%20jointly%20signed%20today.

← DATABASE

Home Database Healthcare & PharmaSTADA

04/2017

STADA acquired by BAIN CAPITAL & CINVEN

GERMANY Life Sciences / Pharma & Biotech / Generics / Labs EV 3b - 100b EUR

Context

The Executive Board and Supervisory Board of STADA agreed to support a voluntary public tender offer from Bain Capital and Cinven. The offer of EUR66.00 per share (including dividend) values the company at an Enterprise Value of approximately EUR5.318 billion. This price represents a premium of roughly 49% over the unaffected share price from December 2016. The deal concludes a highly competitive bidding process (where Advent International was also a contender). The strategic rationale is to delist STADA to allow for a more aggressive long-term growth strategy, unburdened by quarterly public reporting.

STADA, which reported an EBITDA margin of LOGIN in 2017, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in Bad Vilbel, Germany, Stada is a leading European pharmaceutical manufacturer. Historically a generics player, the company has successfully transformed into a diversified "three-pillar" business: Consumer Healthcare (brands like Nizoral, Grippostad, Snup), Generics, and Specialty Pharmaceuticals (including Biosimilars).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2017

2016

Other operations with STADA

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
09/2025	CAPVEST PARTNERS	STADA	GERMANY	Life Sciences	CapVest Partners agreed to acquire a controlling majority stake in Stada from Bain Capital and Cinven. This deal serves as an alternative to a planned IPO in Frankfurt, which was shelved due to market volatility. Under the agreement, the previous owners (Bain and Cinven) will retain a significant minority stake to benefit from future upside. CapVest intends to support the management team's strategy of international expansion and further consolidation in the fragmented consumer health market. Canson Capital Partners is also expected to co-invest alongside CapVest.

REFERENCES

Valuation range: EV 3b - 100b EUR

Revenue range: 1b - 3b EUR

EBITDA range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of STADA by BAIN CAPITAL / CINVEN are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: stada

Acquirer: cinven / bain capital